STARD3NL

Across TCGA pan-cancer cohorts, STARD3NL Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated STARD3NL data layer compared with 27 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher STARD3NL Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated STARD3NL expression acts as an unfavorable survival marker.

CESC and GBM are the cancer types where STARD3NL Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	OS	Median	All	0.261	0.798	.006	12	view →
GBM	DFS	Median	All	0.048	0.242	.006	3	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

STARD3NL–CESC (OS)

Open the CESC breakdown →